Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vigil Neuroscience, Inc. - Common Stock
(NQ:
VIGL
)
2.710
+0.130 (+5.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
46,561
Open
2.620
Bid (Size)
2.610 (2)
Ask (Size)
2.830 (1)
Prev. Close
2.580
Today's Range
2.500 - 2.740
52wk Range
2.500 - 11.11
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
March 26, 2024
VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-21.90%
-21.90%
1 Month
-15.31%
-15.31%
3 Month
-9.06%
-9.06%
6 Month
-68.08%
-68.08%
1 Year
-68.81%
-68.81%
More News
Read More
Vigil Neuroscience: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
February 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 08, 2024
Via
Benzinga
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
January 03, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
November 22, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?
November 17, 2023
Via
Benzinga
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 17, 2023
Via
Benzinga
US Stocks Edge Lower; Housing Starts Rise In October
November 17, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation
October 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 06, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.